Blood cancers, Myeloma
Results
Phase 1
This study looked at adding buparlisib to bortezomib for myeloma to improve treatment.
It was for people who:
had certain gene changes () in their myeloma cells and
whose myeloma had come back or treatment had stopped working
This study was open for people to join between 2016 and 2017. The team reported the results in 2021.
Recruitment start: 23 June 2016
Recruitment end: 14 November 2017
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Kwee Yong
Blood Cancer UK
Janssen
NIHR Clinical Research Network: Cancer
Novartis
University of Birmingham
Last reviewed: 18 May 2022
CRUK internal database number: 12131
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
